



SUPPLEMENTARY MATERIALS:

**Supplementary Figure 1:** Disease extension of Crohn's disease



Supplementary Figure 2: Disease extension of ulcerative colitis

Supplementary Table 1: Risk factors for disease complications in specific IBD centres in Slovenia

| | Academic IBD* centres | | Nonacademic IBD centres | | | | p value |
|-------------------------|-----------------------|---------------|-------------------------|------------------|--------------------|----------------|---------|
| | LJ (n=1950) | MB (n=369) | Celje (n=183) | Izola (n=194) | Jesenice (n=29) | Bled (n=23) | |
| Pancolitis | 630 (32.3%) | 155 (42.0%) | 71 (38.8%) | 65 (33.5%) | 11 (37.9%) | 5 (21.7%) | 0.003 |
| Perianal disease | 191 (9.8%) | 53 (14.4%) | 20 (10.9%) | 14 (7.2%) | 1 (3.4%) | 0 | 0.018 |
| Ileal disease | 248 (12.7%) | 38 (10.3%) | 17 (9.3%) | 17 (8.8%) | 4 (13.8%) | 2 (8.7%) | 0.407 |

*IBD – inflammatory bowel disease

Supplementary Table 2: Number of prescriptions (treatment episodes) of respective lines of therapy

| Line | All | Adalimumab/ biosimilars | Adalimumab/ Humira | Golimumab | Infliximab/ biosimilars | Infliximab/ Remicade | Ustekinumab | Vedolizumab | Others |
|--------------------|------|----------------------------|-----------------------|-----------|----------------------------|-------------------------|-------------|-------------|--------|
| First line | 1687 | 155 | 327 | 61 | 368 | 257 | 149 | 369 | 1 |
| Second line | 703 | 33 | 137 | 11 | 131 | 64 | 151 | 176 | 0 |
| Third line | 280 | 8 | 28 | 4 | 38 | 11 | 105 | 85 | 1 |
| Fourth line | 87 | 5 | 5 | 1 | 8 | 7 | 41 | 19 | 1 |
| Fifth line | 23 | 1 | 3 | 2 | 2 | 0 | 10 | 4 | 1 |
| Sixth line | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total* | 2781 | 203 | 500 | 79 | 547 | 339 | 456 | 653 | 4 |